Şunu aradınız:: swp (İngilizce - Fince)

cpmp/swp/2600/01
cpmp/ swp/ 2600/ 01

1 cpmp/swp/2599/02
1 cpmp/3097/02

cpmp/swp/2877/00 rev.
cpmp/ swp/ 2877/ 00 rev.

emea /cpmp/swp/4163/00
emea/ cpmp/ swp/ 4163/ 00

safety working party (swp)
alankomaat

reference numberdocument titlestatuscpmp/swp/2600/01
cpmp: n turvallisuustyöryhmä viitenumero cpmp/swp/2600/01

cpmp/swp/2877/00 cpmp/swp/4447/00
cpmp/swp/2877/00 cpmp/swp/4447/00 cpmp/swp/446/00

swp conclusions and recommendations with regard to the use of genetically modified animal models for carcinogenicity assessment
note for guidance on photosafety testing note for guidance on specification limits for residues of metal catalysts swp conclusions and recommendations with regard to the use of genetically modified animal models for carcinogenicity assessment

the safety working party (swp) , chaired by dr per sjöberg met twice in 1998.
swp: n yhteyteen perustettiin erityistyöryhmä, joka käsitteli lääkevalmisteiden karsinogeenisuuden uusia tutkimusmenetelmiä.sen puheenjohtajana oli tri per sjöberg.

the swp, in cooperation with the bwp, was involved in the preparation of the dna vaccine and gene therapy related notes for guidance.
safety studies for gene therapy products.

cpmp/swp/4446/00cpmp/3097/02cpmp/swp/799/95
cpmp/swp/799/95 cpmp/swp/5199/02

64 emea annual report 2001reference numberdocument titlestatuscpmp/swp/398/01 cpmp/swp/2600/01note for guidance on photosafety testing points to consider document on the need for reproduction studies in the development of insulin analoguesreleased for consultation march 2001released for consultation september 2001emea herbal medicinal products working partyreference number
viitenumero emea/18123/00emea/hmpwp/31/99 rev 1cvmp: n tehokkuustyöryhmä viitenumero emea/cvmp/016/00 emea/cvmp/005/00 rev 1cvmp/vich/833/99 cvmp/vich/834/99 cvmp/vich/835/99 cvmp/vich/545/00 cvmp/vich/546/00 emea/cvmp/237/01 emea/cvmp/816/00 emea/cvmp/237/01 emea/cvmp/411/01 emea/cvmp/627/01 emea/cvmp/612/01